Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/70
A61K-039/00
A61L-027/20
A61L-027/50
A61L-027/52
A61L-027/54
A61L-027/56
출원번호
US-0112096
(2012-04-27)
등록번호
US-10045947
(2018-08-14)
국제출원번호
PCT/US2012/035505
(2012-04-27)
§371/§102 date
20131227
(20131227)
국제공개번호
WO2012/149358
(2012-11-01)
발명자
/ 주소
Bencherif, Sidi A.
Mooney, David J.
Edwards, David
Sands, Roger Warren
출원인 / 주소
President and Fellows of Harvard College
대리인 / 주소
McCarter & English, LLP
인용정보
피인용 횟수 :
0인용 특허 :
42
초록
The invention provides polymer compositions for cell and drug delivery.
대표청구항▼
1. An injectable cell-compatible highly crosslinked cryogel composition comprising open interconnected pores, wherein said cryogel composition comprises at least 75% pores, and wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle, su
1. An injectable cell-compatible highly crosslinked cryogel composition comprising open interconnected pores, wherein said cryogel composition comprises at least 75% pores, and wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle, such that said cryogel composition returns to its original undeformed three-dimensional shape less than one second after compression through the needle, andwherein said cryogel composition comprises a cryo-crosslinked alginate polymer, wherein said alginate is methacrylated. 2. The cryogel composition of claim 1, comprising at least 90% pores. 3. The cryogel composition of claim 1, comprising at least 90% water when water is within said pores such that said cryogel is in a fully hydrated state. 4. The cryogel composition of claim 1, comprising less than 25% water when compressed. 5. The cryogel composition of claim 1, comprising a cell adhesion composition covalently attached to said polymer. 6. The cryogel composition of claim 5, wherein said cell adhesion composition comprises a peptide comprising an RGD amino acid sequence. 7. The cryogel composition of claim 1, comprising a eukaryotic cell in one or more of said open interconnected pores. 8. The cryogel composition of claim 7, wherein said eukaryotic cell comprises a live attenuated cancer cell. 9. The cryogel composition of claim 1, comprising a biomolecule in one or more of said open interconnected pores. 10. The cryogel composition of claim 9, wherein said biomolecule comprises a small molecule, nucleic acid, or protein. 11. The cryogel composition of claim 10, wherein said protein comprises granulocyte macrophage-colony stimulating factor (GM-CSF). 12. The cryogel composition of claim 10, wherein said nucleic acid comprises a CpG nucleic acid oligonucleotide. 13. The cryogel composition of claim 1, which is injectable through a hollow needle. 14. The cryogel composition of claim 1, wherein upon compression, said cryogel composition maintains structural integrity and shape memory properties. 15. The cryogel composition of claim 1, further comprising gelatin, heparin, dextran, carob gum, PEG, a PEG derivative, collagen, chitosan, carboxymethylcellulose, pullulan, PVA, PHEMA, PNIPAAm, or PAAc. 16. The cryogel composition of claim 1, comprising the shape of a disc, cylinder, square, rectangle, or string. 17. The cryogel composition of claim 1, which is between 100 μm3 to 100 mm3 in size. 18. A method for delivering genetic material to a tissue, comprising administering the cryogel composition of claim 1, wherein said cryogel composition further comprises a nucleic acid. 19. The method of claim 18, wherein said nucleic acid comprises plasmid DNA. 20. A method for eliciting an immune response, comprising administering to a subject the cryogel composition of claim 8. 21. The method of claim 20, wherein said cryogel composition is administered prophylactically or therapeutically. 22. The cryogel composition of claim 1, wherein the highly crosslinked cryogel composition comprises a crosslinking density of at least 50% polymer crosslinking. 23. The cryogel composition of claim 1, wherein the highly crosslinked cryogel composition comprises a crosslinking density of at least 50-100% polymer crosslinking. 24. The cryogel composition of claim 8, wherein said live attenuated cancer cell is a live attenuated melanoma cancer cell. 25. The cryogel composition of claim 4, which returns to its original undeformed three-dimensional shape after it is compressed by up to 90% of its volume. 26. The cryogel composition of claim 1, further comprising a tumor antigen. 27. A syringe comprising (i) a needle, (ii) a reservoir that comprises the cryogel composition of claim 1, and (iii) a plunger. 28. The syringe of claim 27, comprising a 16-gauge, an 18-gauge, a 22-gauge, a 24-gauge, a 26-gauge, a 28-gauge, a 30-gauge, a 32-gauge, or a 34-gauge needle. 29. The syringe of claim 27, comprising an 18 to 30-gauge needle. 30. The syringe of claim 28, wherein the device is between 1 mm3 to 50 mm3 in size. 31. The syringe of claim 28, therein the cryogel composition further comprises live attenuated cancer cells, wherein 90% or more of the cancer cells survive passage of the cryogel composition through the bore of the needle. 32. The syringe of claim 27, wherein the cryogel composition is filled with a physiologically-compatible solution, wherein said cryogel composition is characterized by shape memory following deformation by compression from the reservoir through the needle, such that said cryogel composition returns to its original undeformed three-dimensional shape less than one second after compression from the reservoir through the needle. 33. The cryogel composition of claim 1, wherein said cryogel composition comprises macropores having a diameter of 10 μm to 600 μm. 34. The syringe of claim 27, wherein said cryogel composition comprises macropores having a diameter of 10 μm to 600 μm. 35. The cryogel composition of claim 9, wherein said biomolecule comprises a pathogen-associated molecular pattern (PAMP). 36. The cryogel composition of claim 1, wherein said cryogel composition is characterized by shape memory following deformation by compression from a reservoir of a syringe, in which the cryogel composition is filled with a physiologically-compatible solution, through a needle of the syringe, such that said cryogel composition returns to its original undeformed three-dimensional shape less than one second after compression from the reservoir through the needle. 37. The cryogel composition of claim 1, wherein said cryogel composition comprises a Young's modulus of 4±2 kPa. 38. The syringe of claim 27, wherein the reservoir holds a liquid. 39. The syringe of claim 38, wherein the liquid is a physiologically-compatible solution.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (42)
Huston James S. (Chestnut Hill MA) Oppermann Hermann (Medway MA), Biosynthetic antibody binding sites.
Pardoll Drew ; Azhari Rosa,ILX ; Leong Kam W. ; Golumbe Paul K ; Jaffee Elizabeth ; Levitsky Hyam ; Lazenby Audrey, Controlled release of pharmaceutically active substances for immunotherapy.
Nelson, Kevin D; Romero-Sanchez, Andres A.; Smith, George M.; Alikacem, Nadir; Radulescu, Delia; Waggoner, Paula; Hu, Zhibing, Fabrication of drug loaded biodegradable polymer fibers.
Gaur Amitabh ; Conlon Paul ; Ling Nicholas C. ; Staehelin Theophil,CHX ; Crowe Paul D., Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
Murphy, William L.; Mooney, David J.; Kohn, David H.; Spalding, Gabriel C.; Dearing, Matthew T., Mineral and cellular patterning on biomaterial surfaces.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Hackam, David J.; Gribar, Steven C., Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.